Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3

Interventions

pembrolizumab 1032Carboplatin 969Paclitaxel 942Gemcitabine 799Cisplatin 755Docetaxel 698Bevacizumab 638Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 471Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 345Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 289Irinotecan 271130-nm albumin-bound paclitaxel 256Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 217durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × HBM9161 × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

NCT04346888 2023-03-08

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 2 Completed
30 enrolled

Myasthenia Gravis

NCT05039190 2023-03-08

MG

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
132 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡